ReviewClinical reviews in allergy & immunology2005
Safety and tolerability of omalizumab (Xolair), a recombinant humanized monoclonal anti-IgE antibody.
Review in Clinical reviews in allergy & immunology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pilot Study of the Effect of Omalizumab on Basophil and Mast Responses to Intranasal Cat Allergen Challenge
The Effects of Omalizumab on the Late-phase Response to Nasal Allergen Challenge
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of Omalizumab in the treatment of CSU: a meta-analysis of a randomized controlled trial.Archives of dermatological research · 2025Pooled it
- Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children.The New England journal of medicine · 2011Trial
- Anti-IgE: A treatment option in allergic rhinitis?Allergologie select · 2021Review
- Covalent Heterobivalent Inhibitor Design for Inhibition of IgE-Dependent Penicillin Allergy in a Murine Model.Journal of immunology (Baltimore, Md. : 1950) · 2019Article
- Effects of omalizumab therapy on peripheral nerve functions: short observational study.Postepy dermatologii i alergologii · 2019Article
- Antigen 43/Fcε3 chimeric protein expressed by a novel bacterial surface expression system as an effective asthma vaccine.Immunology · 2014Article
- A heterobivalent ligand inhibits mast cell degranulation via selective inhibition of allergen-IgE interactions in vivo.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Sesame oil attenuates ovalbumin-induced pulmonary edema and bronchial neutrophilic inflammation in mice.BioMed research international · 2013Article
- Omalizumab: the evidence for its place in the treatment of allergic asthma.Core evidence · 2008Article
- Omalizumab for patients with severe and therapy-refractory atopic eczema?Current allergy and asthma reports · 2008Article
- Current and future applications of the anti-IgE antibody omalizumab.Biologics : targets & therapy · 2008Article
- Review
- A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma.Therapeutics and clinical risk management · 2007Article
- Article
- The paradox of adult asthma control: "who's in control anyway?".Canadian respiratory journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Omalizumab (Xolair) is a humanized monoclonal antibody designed to bind specifically to immunoglobulin (Ig)E. It is indicated in the United States for the treatment of adolescent and adult patients (>or=12 yr) with moderate-to-severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen, and whose symptoms are inadequately controlled with inhaled corticosteroids. Omalizumab was evaluated in an extensive clinical development program that included 12 controlled phase IIB/III clinical trials with more than 5,243 patients who were appropriate for inclusion in the safety analysis (all ages in all controlled studies). In these studies, omalizumab had an adverse event profile comparable to that of the control group (i.e., placebo or standard therapy). Data presented in this article supports omalizumab as a safe and well-tolerated agent for the treatment of IgE-mediated asthma.
Indexed as
Identifiers
16222082What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.